Department of Psychiatry, Puerta de Hierro University Hospital-Segovia de Arana Health Research Institute (IDIPHISA), Madrid, Spain.
Biobank, Puerta de Hierro University Hospital-IDIPHISA, Madrid, Spain.
Curr Psychiatry Rep. 2018 Mar 15;20(3):19. doi: 10.1007/s11920-018-0880-4.
The current serotonin-based biological model of suicidal behavior (SB) may be too simplistic. There is emerging evidence that other biomarkers and biological systems may be involved in SB pathophysiology. The literature on the endocannabinoid (EC) systems and SB is limited. The objective of the present article is to review all available information on the relationship between cannabinoid receptors (CB and CB receptors), and SB and/or psychological pain.
Our review is limited by the small number and heterogeneity of studies identified: (1) an autopsy study describing elevated levels of CB receptor activity in the prefrontal cortex and suicide in both depression and alcoholism and (2) studies supporting the involvement of both CB and CB receptors in the regulation of neuropathic pain and stress-induced analgesia. We conclude that cannabinoid receptors, particularly CB receptors, may become promising targets for the development of novel therapeutic tools for the treatment of SB.
目前基于血清素的自杀行为 (SB) 生物学模型可能过于简单。有新的证据表明,其他生物标志物和生物系统可能参与 SB 病理生理学。关于内源性大麻素 (EC) 系统与 SB 的文献有限。本文的目的是回顾所有关于大麻素受体 (CB 和 CB 受体) 与 SB 和/或心理疼痛之间关系的现有信息。
我们的综述受到所确定的研究数量少且异质性的限制:(1) 一项描述在抑郁症和酒精中毒中,自杀者前额叶皮质中 CB 受体活性升高的尸检研究,以及 (2) 支持 CB 和 CB 受体参与调节神经病理性疼痛和应激诱导镇痛的研究。我们得出结论,大麻素受体,特别是 CB 受体,可能成为开发治疗 SB 的新型治疗工具的有前途的靶点。